XENETIC BIOSCIENCES, INC. Other Asset Impairment Charges
XENETIC BIOSCIENCES, INC. (XBIO) reported Other Asset Impairment Charges of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherAssetImpairmentCharges · last filed 2022-03-22
- XENETIC BIOSCIENCES, INC. other asset impairment charges for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- XENETIC BIOSCIENCES, INC. other asset impairment charges for fiscal 2020 was $9.24M.
| Period end | Other Asset Impairment Charges 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-22 |
| 2020-12-31 | $9.24M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |